Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Article Title: Orally Administered Functional Polyphenol-Nanozyme-Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis.
doi: 10.1002/advs.202411939
Figure Lengend Snippet: Figure 6. Therapeutic efficacy of ECA@EcN in a DSS-induced mouse colitis model. A) Schematic representation of the therapeutic evaluation procedure for ECA@EcN in a DSS-induced colitis model. B) Body weight variations in mice subjected to different treatments. C) Changes in disease activity index (DAI) during treatment. D,E) Colon tissue images and corresponding quantified colon lengths after various treatments. F,G) H&E-stained histological images of colon tissues and corresponding histopathological scores. Scale bar: 100 μm. H) Serum levels of TNF-𝛼, IL-6, and IL-1𝛽measured by ELISA on day 13. I) Representative immunofluorescence images of claudin-1 (green) and ZO-1 (yellow) with DAPI (blue) nuclear counterstaining. Scale bar: 100 μm. All data are presented as the means ± SD (n = 6). Statistical analysis was performed using one-way ANOVA. *p < 0.05; ns, not significant.
Article Snippet: 3,3′,5,5′-Tetramethylbenzidine (TMB: ST746), DCFH-DA fluorescent probe, Total SOD Assay Kit with WST-8 (Cat# S0101S), Catalase Assay Kit (Cat# S0051), Hoechst 33342 (Cat# C1028), and DAPI fluorescent probe were acquired from Beyotime Biotechnology Co., Ltd. (Shanghai, China).
Techniques: Activity Assay, Staining, Enzyme-linked Immunosorbent Assay